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Phase I trial of metastatic renal cell carcinoma with oral
capecitabine and thalidomide
Phase-I-Studie zum metastasierten Nierenzellkarzinom mit oralem
Capecitabin und Thalidomid
Abstract
Background: The highly vascular nature of renal carcinoma cells sug-
gests that inhibition of angiogenesis may be beneficial in this disease.
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Thalidomide has been described as inhibitor of the fibroblast growth
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factor(FGF)andthevascularendothelialgrowthfactor(VEGF).Therefore
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1 andinconsiderationofthepromisingresponseratesofthecombination
of IL-2, IFN-alpha and 5-FU [1] in metastatic renal cancer, we found it Stefan C. Müller
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reasonable to test the combination of 5-FU and thalidomide. Thus, we
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conductedaphaseItrialtodeterminesafety,sideeffectsandresponses
to such a treatment. Ingo G. H. Schmidt-
Wolf
1 Methods:Patientswithmetastasizedrenalcellcancerafternephrectomy
and progress after IL-2 and interferon treatment, received oral 5-FU at
a dose of 1250 mg/qm
2 twice a day for two weeks, then after pausing
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aweek,theoralapplicationwasrestarted.Inaddition,oralthalidomide
wasappliedconstantlyatamaximumdoseof400mg/d.Thecombined
therapywasgivenforthreemonths.Theprimaryendpointwasduration
until disease progression, the secondary endpoint the response to 2 Department of Urology,
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treatment. Response was determined by CT scans three months after
the end of treatment.
Results: In total, 12 male patients participated in the trial and received
the combined oral therapy. Concerning clinical response, one mixed
response(8%),astablediseasein4/12patients(33%)andprogression
was seen in 7 patients (58%). The survival from the start of the therapy
showed a median of 21 months with three patients being alive. At
present, the longest survival after the therapy is 51 months.
Conclusions: The combination of oral 5-FU and thalidomide showed
clinical response with tolerable side effects. Further studies will be re-
quired to assess the outcome of this treatment regimen.
Keywords:metastasizedrenalcellcarcinoma,5-FU,thalidomide,phase
I trial
Zusammenfassung
Hintergrund: Die hohe Vaskularisierung beim Nierenzellkarzinom legt
nahe, dass eine Inhibition der Angiogenese bei dieser Erkrankung von
Vorteil sein könnte. Thalidomid wurde als Inhibitor von FGF (Fibroblas-
tenwachstumsfaktor) und VEGF (vaskulärer endothelialer Wachstums-
faktor) beschrieben. Deshalb und aufgrund der erfolgversprechenden
Daten von Interleukin-2, Interferon-alpha und 5-FU [1] testeten wir die
Kombination von Thalidomid und 5-FU. Wir führten eine Phase-I-Studie
zur Testung von Sicherheit und Verträglichkeit durch.
Methoden: Patienten mit metastasiertem Nierenzellkarzinom nach
Nephrektomie und Progress nach IL-2 und Interferon-Behandlung er-
hieltenorales5-FUineinerDosierungvon1250mg/qm
2zweimaltäglich
über 2 Wochen. Nach einer einwöchigen Pause, wurde die Behandlung
fortgesetzt. Zusätzlich wurde Thalidomid kontinuierlich bis zu einer
maximalen Dosis von 400 mg/Tag gegeben. Diese Kombination erhiel-
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Short Communication OPEN ACCESSten die Patienten über 3 Monate. Primärer Endpunkt war die Dauer bis
zur Progression der Krankheit, sekundärer Endpunkt das Ansprechen
auf die Therapie. Das Ansprechen wurde mittels CT 3 Monate nach
Ende der Therapie bestimmt.
Ergebnisse: 12 männliche Patienten nahmen an dieser Studie teil. Ein
gemischtes Ansprechen (8%), 4 stabile Erkrankungen (33%) und
7 Progresse (58%) wurden gesehen. Das mittlere Überleben betrug 21
Monate mit jetzt noch 3 lebenden Patienten. Zur Zeit beträgt das
längste Überleben 51 Monate.
Schlussfolgerung: Die Kombination von oralem 5-FU und Thalidomid
zeigte bei diesen überwiegend vortherapierten Patienten klinisches
Ansprechen bei tolerablen Nebenwirkungen. Weitere Studien sind not-
wendig, um den Stellenwert dieser Kombination nach Gabe der neuen
TherapieoptionenbeimmetastasiertenNierenzellkarzinomzuuntersu-
chen.
Introduction
The frequency of the renal cell carcinoma is increasing.
A prevalence of 9/100.000 inhabitants in Germany and
more than 30.000 new diagnoses in Europe underlines
its enormous importance.
Renal cancer shows a peak of the disease at the ages
between 50 and 70 years. A third of the patients with
renal cell carcinoma present with metastases, mostly of
the lung (60%), liver (25%) and skeleton system (25%).
Acommontherapyisyettobeestablished,whiledifferent
strategies have been tested until now. The combination
of IL-2 and IFN-alpha (plus 5-FU) showed a response rate
of 37% [1].
Clear renal cell carcinoma is the major histological type.
Thetumorshowsahighexpressionofvascularendotheli-
algrowthfactor(VEGF)andplatelet-derivedgrowthfactor
(PDGF). Therefore, we used thalidomide, which has anti-
angiogenetic and immunomodulatory properties, which
showed a prolonged duration until disease progression
in phase II studies in patients with metastasized renal
cell carcinomas [2]. Showing neurotoxical side effects
suchasperipheralneuropathianeccesitatingdosereduc-
tions after prolonged therapy with thalidomide alone, we
decidedtobaseourtherapyonacombinationwithdiffer-
ent chemotherapy [3].
Former studies described the use of 5-FU as a treatment
formetastasizedrenalcellcarcinomaincombinationwith
IL-2 and IFN-alpha. This combination showed an overall
response rate of 37%, while lowering the toxicity of an
aggressiveIL-2treatment[1].Beingusedinthetreatment
of colo-rectal carcinoma and breast cancer patients, it
has also shown its efficacy in renal cell carcinoma (RCC)
in several studies [4], [5].
Materials and methods
Patients
ThisphaseItrialhasbeenconductedbetween2003and
2006 and included 12 patients with metastasized renal
cell carcinoma.
Criteriaeforparticipatinginthestudyhasbeenhistologic-
ally confirmed renal cell carcinoma at stage IVA, age 18
years or older, exclusive treatment in this study and an
interval of lack of chemotherapy for at least two months.
Patients signed written consent forms as approved by
the local ethics committee.
Evaluation before, during and after
treatment
The evaluation before treatment included a physical ex-
amination, a complete blood count, the Karnofsky index
and a thorax and abdominal CT. The blood count was
controlled every month in addition to liver function test
and renal parameters such as creatinine. Posttreatment
evaluations included the same parameters as the pre-
treatment evaluation.
Treatment and follow-up studies
Patients, who had filled in the main criteria for the study,
had been given 1250 mg/qm
2 5-FU orally for two weeks,
twice a day. Then after a pause for one week, the two-
weekly cycle started again. Meanwhile the patients re-
ceived constantly thalidomide at an individual dose, with
an upper limit of 400 mg/d. Follow-up studies concen-
trated on a complete blood count, the subjective side ef-
fects of the therapy and post-treatment CT.
Assessment of efficacy
All patients where regularly evaluated for their subjective
feelingofsideeffects.Theresponsetothechemotherapy
was evaluated after three months of treatment. The effi-
cacy was jugded by the Response Evaluation Criteria in
solid tumors (RECIST).
Statistical methods
Primary endpoint was the duration until disease progres-
sion, the secondary endpoint was response rate. In par-
allel, we concentrated on toxicity, which had been as-
signed by using the toxicity scale of the World Health Or-
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ganisation (WHO), the response rate was assessed by
the RECIST criteria [6].
Results
Twelve patients participated in this phase I study and
received the combined therapy. Table 1 summarizes the
characteristics of the patients, their individual tumor
stage, the grading and their systemic pretreatment. Me-
dian age was 58 years at the time of diagnosis. First, 11
of12patientshadbeennephrectomized,while8ofthem
hadreceivedsystemictreatmentwithIL-2andIFN-alpha.
Response to treatment and duration
until disease progression
The duration until disease progression had been evalu-
ated by CT. The following criteriae had been used to
define the results: CR: reduction to 0% tumor; PR: reduc-
tion to 1–50% tumor; MR: reduction 50–75% tumor,
SD/NC: 75–125% tumor; PD>125% tumor.
Theoverallresponseshowedaprogressionofmetastases
in 58% (7/12 patients), a stable disease in 33% (4/12)
and a mixed response in 8% (1/12). Response seemed
to show a correlation to the location of the metastases.
The filiae in the lung seemed to be less responsive in
comparison to the lymph nodule metastases, which
showed a CR in one case. The duration until disease
progression or regression was controlled individually
between the first and third month after starting the ther-
apy.
Thekindofresponseafterthefirstmonthcorrelatedwith
the overall success or failure of the therapy. The patients
who showed a lack of progression mostly stayed at a
stable disease or showed a MR.
Thosewhosemetastasesincreasedinvolumeornumbers
showed no response in the follow-up evaluations of the
combined medication of thalidomide and 5-FU.
Toxicity
Themostcommonsideeffectsweregastrointestinalsuch
asnausea,vomittingdiarrheaorconstipation(88%).Pain
of the limbs were observed in 63%. Another side effect
that seemed to be typical was the paresthetical feeling
oftheextremities(63%),especiallythefeet.Exanthemas
were frequent (25%).
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Kraemer et al.: Phase I trial of metastatic renal cell carcinoma with ...Figure 1: Overall survival of all 12 patients treated with oral 5FU plus thalidomide
The blood count showed no side effect. There was no
liver or renal toxicity. Eleven patients received the com-
plete dose of the chemotherapy except for one patient,
who needed a dose reduction of 50%. One participant
was excluded from the study because of unbearable
paresthetical feelings.
Outcome and survival
At the end of the study, 75% (9/12 patients) had died of
their disease. The longest survival showed a duration of
51 months (see Figure 1). Our study focused on the side
effects the patients suffered under during the combinat-
ory therapy. Those seemed to be tolerable.
In particular, the often described thrombosis under
thalidomidetherapydidnotappearinthisstudy,although
thrombocytes raised during the treatment.
The raising of the thrombocytes was in none of the cases
a reason for dose reduction or pausing of the therapy.
The response to the therapy has to be established in
further studies.
Discussion
In comparison to the studies of Hofmockel et al. [1],
where IL-2, IFN-alpha and 5-FU had been given and the
thalidomide/IL-2 therapy by Schrader et al. [7], the
treatment of this phase I study consisted of thalidomide
in combination with 5-FU.
While the treatment of Hofmockel et al. showed a prom-
ising response rate with 2 CR, 9 PR and an overall re-
sponse rate of 37% with mild side effects, the therapy
with thalidomide/IL-2 showed lower response rates and
higher side effects.
Combining 5-FU with thalidomide allowed a dose reduc-
tionandthereforeminorsideeffectsduringthetreatment
with thalidomide. With an overall response rate of 41.6%
and minor side effects containing mostly constipation
and paresthetical feelings of the limbs, just one of the
participants discontinued treatment because of side ef-
fects.
Withthreepatients,whosurvivedsincestartingthestudy,
the longest survival being 51 months, the outcome for
the patients seemed to have improved for the patients
who responded to the therapy in the first three months.
In their review, Hilles JJ and Kolesar JM reported of the
useofsunitinibandsorafenib,bothtyrosinekinaseinhib-
itors with a potency in inhibiting the vascular endothelial
growth factor (VEGF) receptors and the platelet-derived
growth factor (PDGF) and therefore having an antitumor
and antiangiogenic effect are also showing improved
outcomesforpatientswithRCC[8].Sunitinibisnowused
as treatment for metastatic renal cancer patients. In ad-
dition, sorafenib demonstrated to have a positive influ-
enceonthesurvivalofpatientswithmetastaticrenalcell
carcinoma in a phase III study [8].
As side effects of this therapy new studies described an
inducedmacrocytosisunderthetreatmentwithsunitinib.
This increase of the mean corpuscular volume (MCV)
seemedtoappearespeciallyinpatientswithadiagnosed
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therapy. Cytopenia was reported with the use of both
drugs[9].Sunitinibinducedhypothyreodismasacommon
side effect, which can be medically substituted with oral
thyroide hormone replacement [10].
Another way of inhibiting the VEGF is the use of the hu-
manised anti-VEGF monoclonal antibody bevacizumab.
This has been combined with IFN-alpha. The results of
this study showed a progression-free survival of 10.2
months[11].IncomparisontotheapplicationofIFN-alpha
alone,thecombinationofbothdrugsshowedasignificant
improvementinprogressionfreesurvival[12].Thetoxicity
of IFN-alpha alone explains the necessity to search for a
therapy with minor side effects while showing at least a
similary response.
According to the EAU-Guidelines, the standard first and
second line treatment for patients with metastasized
renal cancer is tyrosin kinase inhibitors, since they in-
crease progression-free survival. Hudes G. et al. showed
in a comparison of temsirolimus, a specific inhibitor of
the mammalian target of rapamycin kinase, to IFN-alpha
alone, that temsirolimus treated patient improved in the
overall survival by showing minor side effects. In particu-
lar, poor prognosis patients improved under the treat-
ment,whileacombinationoftemsirolimuswithIFN-alpha
hadnosignificanteffectattheoverallsurvivalincompari-
son to temsirolimus alone [13].
Our study is in accordance with a recent trial on the use
ofthalidomideplusinterleukin-2andGM-CSFinpatients
with metastatic renal cancer [14]. Comparing our study
with the latest studies with our treatment our patients
showedanoverallsurvivalupto51months,withtolerable
side effects of the chemotherapy. The results seem to
show that a response to the therapy can be seen in the
first three months. Those who were responding to the
therapy showed an improvement of their disease, while
the side effects of the therapy were minor.
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